Brown, Lisle/Cummings’s BioNTech BNTX Stock Holding History

Brown, Lisle/Cummings’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$1K	–	777
2025 Q1	$1K	Buy	+11	New	+$1.23K	﹤0.01%	709

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown, Lisle/Cummings's BNTX Position: Q2 2025 in Review

Brown, Lisle/Cummings sold out of BioNTech (BNTX) in Q2 2025, closing a stake of 11 shares — an estimated $1K sold.

Brown, Lisle/Cummings first reported a position in BNTX in Q1 2025 and held it in 1 quarter. The position peaked at $1K in Q1 2025. 258 funds tracked by Wall St. Rank hold BNTX as of Q2 2025.

Brown, Lisle/Cummings reported no remaining BioNTech position as of Q2 2025 after selling out during the quarter.
Brown, Lisle/Cummings sold 11 BioNTech shares in Q2 2025, an estimated $1K.
Brown, Lisle/Cummings first reported a position in BioNTech in Q1 2025 and held it in 1 quarter.
Brown, Lisle/Cummings's BioNTech position peaked at $1K in Q1 2025.
258 funds tracked by Wall St. Rank held BioNTech as of Q2 2025.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2025, filed 16 Jul 2025.